查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1939565

呼吸道气溶胶输送装置市场按装置类型、产品类型、便携性和最终用户划分，全球预测（2026-2032年）

Pulmonary Disease Aerosol Delivery Devices Market by Device Type, Product Type, Portability, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺部气溶胶输送装置市值将达到 25 亿美元，到 2026 年将成长至 27.9 亿美元，到 2032 年将达到 56.7 亿美元，复合年增长率为 12.39%。

关键市场统计数据
基准年 2025 25亿美元
预计年份：2026年 27.9亿美元
预测年份 2032 56.7亿美元
复合年增长率 (%) 12.39%

整合临床因素、技术进步、监管预期和供应链实际情况的策略方向正在塑造肺部疾病气溶胶装置的发展。

本执行摘要概述了肺部疾病气雾剂输送装置的现状和近期发展趋势，并平衡了临床需求、技术进步和监管压力——这些因素都会影响相关人员的优先事项。过去十年，人们对治疗的期望已转向精准给药、遵守用药以及与数位健康工具的整合，这推动了装置的重新设计以及製药和医疗设备製造商之间的新合作。同时，支付方和医疗服务提供者越来越关注实际疗效和总医疗成本，因此更加重视可证实的临床价值和易用性。

器械工程、以病人为中心的设计、供应链现代化和监管合作如何重塑商业竞争和临床应用

肺部气溶胶输送装置领域正经历多重变革，这些变革正在重塑产品的研发、检验和上市方式。首先，装置机械结构和製剂科学的进步降低了剂量变异性，提高了装置可靠性，从而能够与数位化依从性工具和远端监测平台更紧密地整合。这种机械精度与软体智慧的结合，正迫使製造商重新思考使用者介面、部署流程和资料安全措施。

评估2025年美国关税调整对供应链、采购和监管的累积影响

2025年美国关税调整已对现有的医疗设备采购和製造模式造成了显着影响，筹资策略、生产计画和成本管理技术产生了累积性影响。依赖进口的製造商面临关键零件和子组件更高的到岸成本，这促使他们重新评估全球供应商网路并加速推进近岸外包计画。许多公司正在采取应对措施，例如实现供应商多元化和增加缓衝库存，以缓解短期供应中断的影响。

详细的細項分析重点阐述了设备类型、产品品牌、分销管道、临床环境和便携性等因素如何区分相关人员的优先事项。

细分市场层面的趋势揭示了不同设备类型、产品类型、分销管道、最终用户和便携性方面存在差异化的需求模式和战略意义。依设备类型（包括干粉吸入器、喷射式雾化器、网式雾化器和超音波雾化器等雾化器，以及定量喷雾吸入器和缓雾吸入器）分析，易用性、剂量准确性和对特定临床人群的适用性之间存在明显的权衡取舍。例如，雾化器内部的差异凸显了其效能、维护需求以及在不同医疗环境中不同的临床应用情境和采购偏好。

区域分析突显了美洲、欧洲、中东和非洲以及亚太市场在采用驱动因素、报销复杂性和基础设施发展方面的差异

区域趋势正在影响三大宏观区域（美洲、欧洲、中东和非洲以及亚太地区）的采纳路径和竞争策略。在美洲，支付方结构、公私报销机制以及对基于结果的采购的高度重视，对采纳过程产生了显着影响。这种环境鼓励采用基于真实世界数据和整合式医疗路径的实证解决方案，同时也推动了能够提供全面服务能力的供应商之间的整合。

对竞争格局进行综合分析，重点在于现有和新兴设备公司所采取的策略联盟、创新蓝图和商业化方法。

肺部气雾装置领域主要企业的发展趋势凸显出两极化：一方面是不断拓展平台功能的成熟企业，另一方面新兴企业。老牌製造商持续投资于剂量均匀性、患者人体工学和生产效率的迭代改进，而新参与企业则倾向于专注于数位整合、特殊配方或特定临床领域。製药公司与装置专家之间的合作日益普遍，从而能够共同开发整合吸入技术和药物输送功能的治疗方案。

为协调研发重点、供应链策略和商业模式以推动技术应用并保持竞争优势，提供实际有效的建议。

为了充分利用不断发展的呼吸照护模式，产业领导者应采取整合产品设计、法规遵循和供应链韧性的策略。在早期研发阶段优先考虑人体工学和实证医学证据，将有助于减少后续监管方面的阻力，并加强医保报销谈判。企业必须整合临床、技术和商业职能，并行而非顺序地满足使用者需求、可生产性和支付方的证据要求。

我们透明的调查方法，清楚地概述了主要和次要资料收集方法、检验流程和分析保障措施，使我们能够得出可靠的、可操作的结论。

本研究采用系统性的调查方法，综合分析了一手和二手证据，以确保分析的严谨性和可操作性的洞见。资料收集包括对临床医生、采购主管、医疗设备工程师和支付方代表的定向访谈，以及对器械规格、监管申报文件和人体工学研究的技术审查。透过对这些资讯进行三角验证，以检验产品性能声明，识别推广障碍，并梳理医院、诊所和居家照护机构的决策标准。

最终综合战略意义、营运重点和合作伙伴关係，组织应采取这些措施来推进肺部气溶胶疗法的创新。

总之，目前肺部气溶胶输送装置领域呈现出快速的技术进步、不断变化的监管要求和不断演变的采购趋势，这些因素共同创造了策略机会和营运风险。装置性能本身并非成功的唯一决定因素；与数位化检验的整合、已证实的临床和经济价值以及稳健的生产和筹资策略同样至关重要。因此，相关人员必须采取多学科协作的方式，将卓越的工程技术、临床验证和商业性现实结合。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 呼吸道气溶胶输送装置市场（依装置类型划分）

  • 干粉吸入器
  • 喷雾器
    • 喷射式雾化器
    • 网状雾化器
    • 超音波雾化器
  • 压力定量吸入器
  • 缓雾吸入器

9. 呼吸道气溶胶输送装置市场（依产品类型划分）

  • 品牌产品
  • 非专利的

10. 呼吸气溶胶输送设备市场（依便携性划分）

  • 不可携带式
  • 携带式的

11. 依最终用户分類的呼吸道气溶胶输送设备市场

  • 诊所
  • 居家照护
  • 医院

12. 各地区呼吸道气溶胶输送装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 呼吸气溶胶输送装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国呼吸道气溶胶输送装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国呼吸气溶胶输送装置市场

16. 中国呼吸系统疾病气雾剂输送装置市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Aerogen Limited
  • AptarGroup, Inc.
  • Becton, Dickinson and Company
  • Koninklijke Philips NV
  • Merck & Co., Inc.
  • Nemera SA
  • Novartis AG
  • Omron Corporation
  • PARI GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Vyaire Medical, Inc.
  • West Pharmaceutical Services, Inc.
Product Code: MRR-9A6A6F29785E

The Pulmonary Disease Aerosol Delivery Devices Market was valued at USD 2.50 billion in 2025 and is projected to grow to USD 2.79 billion in 2026, with a CAGR of 12.39%, reaching USD 5.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.50 billion
Estimated Year [2026] USD 2.79 billion
Forecast Year [2032] USD 5.67 billion
CAGR (%) 12.39%

Strategic orientation synthesizing clinical drivers, technological advances, regulatory expectations, and supply chain realities shaping pulmonary aerosol device development

This executive introduction frames the current state and near-term dynamics of pulmonary disease aerosol delivery devices, balancing clinical needs, technological evolution, and regulatory pressures that jointly influence stakeholder priorities. Over the past decade, therapeutic expectations have shifted toward precision dosing, improved adherence, and integration with digital health tools, which has driven device redesign and renewed collaboration between pharmaceutical and device manufacturers. Simultaneously, payers and providers have grown more attentive to real-world outcomes and total cost of care, prompting an emphasis on demonstrable clinical value and usability.

As device makers navigate an increasingly complex ecosystem, supply chain resilience and manufacturing flexibility have moved up organizational agendas. Regulatory pathways are evolving to accommodate combination products and software-enabled devices, while reimbursement frameworks adapt to evidence of long-term benefits. Against this backdrop, clinicians and procurement teams are reassessing criteria for device selection to include lifecycle costs, training requirements, and patient experience.

This introduction therefore establishes the strategic imperatives that will recur across the report: the need for human-centered design, evidence generation aligned with payer expectations, regulatory foresight, and supply chain diversification. These imperatives inform decision-making for manufacturers, investors, and healthcare organizations that seek to align innovation with scalable commercial pathways.

How device engineering, patient-centric design, supply chain modernization, and regulatory collaboration are reshaping commercial competition and clinical adoption

The landscape for pulmonary aerosol delivery devices is undergoing several concurrent transformational shifts that are reshaping how products are developed, validated, and brought to market. First, advances in device mechanics and formulation science have reduced variability in dose delivery and enhanced device reliability, which in turn supports tighter integration with digital adherence tools and remote monitoring platforms. This convergence of mechanical precision and software intelligence is prompting manufacturers to rethink user interfaces, onboarding workflows, and data security practices.

Second, patient-centricity has moved beyond feature lists to become a primary design criterion; devices are now judged by their ease of use across diverse populations, including pediatric and geriatric cohorts. Third, manufacturing and supply chain modernization-leveraging modular production, strategic sourcing, and localized assembly-has improved responsiveness to demand fluctuations and regulatory audits. Fourth, regulatory bodies are shifting toward more collaborative review processes for combination products and software as a medical device, which requires earlier engagement and more robust clinical and human factors evidence.

Finally, competitive dynamics are influenced by strategic partnerships between device makers, pharmaceutical companies, and digital health firms, fostering bundled solutions that emphasize outcome-based value. Collectively, these shifts are creating a landscape where multidisciplinary capabilities, regulatory agility, and evidence-driven design determine market momentum and long-term adoption.

Evaluating the cumulative supply chain, sourcing, and regulatory consequences stemming from United States tariff recalibrations introduced during 2025

The United States tariff adjustments implemented in 2025 have introduced measurable friction into established procurement and manufacturing models for medical devices, with cumulative effects that extend across sourcing strategies, production planning, and cost-management practices. Import-dependent manufacturers have encountered higher landed costs for critical components and subassemblies, which in turn have incentivized the reassessment of global supplier networks and the acceleration of nearshoring initiatives. Many firms have responded by diversifying vendor bases and increasing buffer inventories to mitigate short-term supply disruptions.

In parallel, procurement teams within healthcare systems and distributors have recalibrated contract terms to account for greater supplier price variability and potential lead-time volatility. This has influenced negotiations around long-term supply agreements and service-level commitments. For product developers, tariff-induced cost pressures are prompting design reviews with a focus on material substitution, component consolidation, and manufacturability improvements that preserve clinical performance while reducing exposure to tariff-exposed inputs.

Regulatory compliance and quality assurance considerations have compounded these adjustments, as any change in supplier or component can trigger additional validation efforts. Consequently, organizations that proactively align sourcing, engineering, and regulatory teams demonstrate greater resilience. Looking ahead, the cumulative impact of the tariff environment favors supply chain transparency, strategic supplier partnerships, and investment in flexible production capacity as means to sustain product availability and protect margins.

In-depth segmentation insights highlighting how device types, product branding, distribution channels, care settings, and portability considerations drive differentiated stakeholder priorities

Segment-level dynamics reveal differentiated demand patterns and strategic implications across device type, product type, distribution channels, end users, and portability dimensions. When examined by device type-Dry Powder Inhalers, Nebulizers including Jet Nebulizers, Mesh Nebulizers, and Ultrasonic Nebulizers, Pressurized Metered Dose Inhalers, and Soft Mist Inhalers-there are clear trade-offs between ease of use, dosing precision, and suitability for specific clinical populations. The internal variation within nebulizers, for example, underscores divergent clinical use-cases and procurement preferences driven by performance, maintenance needs, and setting of care.

The split between Branded and Generic product types shapes manufacturer strategies around lifecycle management, product differentiation, and evidence generation. Branded solutions typically emphasize proprietary enhancements, integrated services, and bundled therapeutic value, whereas generics compete on cost, reliability, and supply continuity. Distribution channel dynamics-Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy-reflect evolving buyer journeys and logistics considerations; hospital pharmacies prioritize clinical compatibility and service contracts, while online and retail channels prioritize patient convenience and home delivery capabilities.

End user segmentation-Clinic, Home Care, and Hospital-reveals divergent requirements for device ruggedness, training intensity, and remote monitoring functionality. Portability distinctions between Non Portable and Portable offerings further inform product design, with portable devices emphasizing battery management, compactness, and user feedback mechanisms. Together, these segmentation lenses provide a nuanced roadmap for product development, commercialization, and post-market support strategies.

Regional analysis emphasizing distinct adoption drivers, reimbursement complexities, and infrastructure readiness across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics shape adoption pathways and competitive strategies across the three macro regions of the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, adoption is heavily influenced by payer structures, private and public reimbursement mechanisms, and a strong emphasis on outcomes-based procurement. This environment often rewards solutions backed by real-world evidence and integrated care pathways, while also encouraging consolidation among suppliers that can offer comprehensive service capabilities.

In Europe, Middle East & Africa, regulatory harmonization initiatives and diverse reimbursement landscapes create both opportunities and complexity. Manufacturers must navigate varied national processes and demonstrate adaptability in pricing and clinical evidence packages. Health system heterogeneity in this region also favors flexible commercial models and local partnerships to ensure market access and sustained uptake.

In Asia-Pacific, rapid urbanization, expanding healthcare infrastructure, and a strong focus on local manufacturing capabilities drive a distinct set of priorities. Cost sensitivity and scale considerations are important, but there is also notable appetite for digital health integration and mobile-enabled adherence solutions. Across all regions, infrastructure readiness, clinician training, and distribution channel maturity remain critical determinants of how quickly new device innovations achieve meaningful clinical integration and adoption.

Competitive landscape synthesis revealing strategic partnerships, innovation roadmaps, and commercialization approaches pursued by both incumbents and emerging device challengers

Key company dynamics in the pulmonary aerosol device space highlight a mix of incumbents extending platform capabilities and agile challengers introducing niche innovations. Established manufacturers continue to invest in iterative improvements to dosing consistency, patient ergonomics, and manufacturing efficiency, while newer entrants often focus on digital integration, specialized formulations, or targeted clinical segments. Partnerships between pharmaceutical companies and device specialists are increasingly common, enabling co-development of integrated therapeutic solutions that align inhalation technology with drug delivery performance.

Strategic collaboration extends beyond co-development into distribution and service models, with some firms pursuing value-added services such as training programs, remote adherence monitoring, and bundled maintenance contracts. Companies that can demonstrate robust evidence of clinical benefit, reduced caregiver burden, or demonstrable improvements in adherence gain preferential consideration from health systems and payers. Meanwhile, private equity and corporate investors are monitoring the sector for consolidation opportunities, particularly among companies with differentiated IP or access to desirable clinical datasets.

Innovation roadmaps emphasize software-enabled features, improved materials science, and scalable manufacturing platforms that reduce unit costs without sacrificing fidelity. Competitive positioning increasingly relies on the ability to integrate device hardware, drug formulation expertise, and digital analytics into coherent propositions that address both clinical outcomes and operational efficiencies for healthcare providers.

Practical, high-impact recommendations for aligning R&D priorities, supply chain strategies, and commercial models to accelerate adoption and sustain competitive advantage

Industry leaders should adopt a coordinated strategy that aligns product design, regulatory engagement, and supply chain resilience to capitalize on evolving pulmonary treatment paradigms. Prioritizing human factors and evidence generation early in the development cycle will reduce downstream regulatory friction and strengthen reimbursement dialogues. Firms should integrate clinical, engineering, and commercial teams to ensure that user needs, manufacturability, and payer evidence requirements are addressed in parallel rather than sequentially.

On the supply side, diversifying supplier relationships and investing in modular manufacturing capabilities can mitigate exposure to geopolitical and tariff-related disruptions. Strategic nearshoring, multi-sourcing critical components, and applying rigorous supplier qualification processes will enhance continuity while preserving flexibility. From a go-to-market perspective, developing tailored value propositions for hospital pharmacy, online and retail channels, and clinic and home care settings will improve alignment with buyer priorities and patient use-cases.

Lastly, leaders should evaluate partnerships with digital health firms to add adherence monitoring and analytics capabilities that enhance product differentiation. Where appropriate, companies should explore outcome-based contracting and post-market evidence programs that demonstrate clinical and economic value, thereby facilitating broader acceptance among payers and providers.

Transparent research methodology describing primary and secondary data collection, validation processes, and analytical safeguards that ensure robust and actionable conclusions

This research synthesizes primary and secondary evidence through a structured methodology designed to ensure analytical rigor and actionable findings. Data collection included targeted interviews with clinicians, procurement leaders, device engineers, and payer representatives, complemented by technical reviews of device specifications, regulatory filings, and human factors studies. Triangulation across these inputs was used to validate product performance claims, identify adoption barriers, and map decision-making criteria employed by hospitals, clinics, and home care providers.

Analytical procedures incorporated comparative assessments of device architectures, materials, and maintenance requirements, alongside scenario analyses that examined supply chain resilience and sourcing alternatives. The methodology emphasized reproducible evaluation of human factors evidence, clinical usability studies, and the regulatory context for combination products and software-enabled devices. Where possible, findings were cross-checked against publicly available regulatory determinations and peer-reviewed literature to ensure consistency.

Quality assurance protocols included peer review by subject matter experts and iterative refinement of hypotheses based on stakeholder feedback. Limitations of the research are explicitly noted, and recommendations are framed to be adaptive to emerging clinical data and evolving regulatory guidance, ensuring that the study's conclusions remain relevant to strategic decision-makers.

Final synthesis of strategic implications, operational priorities, and partnership imperatives that organizations must act upon to advance pulmonary aerosol therapy innovation

In conclusion, the pulmonary aerosol delivery device landscape is characterized by rapid technological progress, shifting regulatory expectations, and evolving procurement dynamics that together shape strategic opportunities and operational risks. Device performance alone is no longer the sole determinant of success; integration with digital monitoring, evidence of clinical and economic value, and resilient manufacturing and sourcing strategies are equally important. Stakeholders must therefore adopt multidisciplinary approaches that align engineering excellence with clinical validation and commercial pragmatism.

Regulatory engagement and early evidence planning are essential to streamline market entry and to support reimbursement conversations. Supply chain diversification and manufacturing flexibility provide vital protection against tariff related and geopolitical disruptions. Finally, segmentation and regional insights underscore that one-size-fits-all strategies are unlikely to succeed; instead, tailored value propositions that account for device type nuances, distribution channel requirements, care setting realities, and regional healthcare system characteristics will drive sustained adoption.

Taken together, these conclusions offer a strategic lens for investors, manufacturers, clinicians, and policymakers to prioritize actions that balance innovation with practical pathways to clinical integration and commercial uptake.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Disease Aerosol Delivery Devices Market, by Device Type

  • 8.1. Dry Powder Inhalers
  • 8.2. Nebulizers
    • 8.2.1. Jet Nebulizers
    • 8.2.2. Mesh Nebulizers
    • 8.2.3. Ultrasonic Nebulizers
  • 8.3. Pressurized Metered Dose Inhalers
  • 8.4. Soft Mist Inhalers

9. Pulmonary Disease Aerosol Delivery Devices Market, by Product Type

  • 9.1. Branded
  • 9.2. Generic

10. Pulmonary Disease Aerosol Delivery Devices Market, by Portability

  • 10.1. Non Portable
  • 10.2. Portable

11. Pulmonary Disease Aerosol Delivery Devices Market, by End User

  • 11.1. Clinic
  • 11.2. Home Care
  • 11.3. Hospital

12. Pulmonary Disease Aerosol Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pulmonary Disease Aerosol Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pulmonary Disease Aerosol Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pulmonary Disease Aerosol Delivery Devices Market

16. China Pulmonary Disease Aerosol Delivery Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. Aerogen Limited
  • 17.7. AptarGroup, Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Koninklijke Philips N.V.
  • 17.10. Merck & Co., Inc.
  • 17.11. Nemera SA
  • 17.12. Novartis AG
  • 17.13. Omron Corporation
  • 17.14. PARI GmbH
  • 17.15. Teva Pharmaceutical Industries Ltd.
  • 17.16. Vyaire Medical, Inc.
  • 17.17. West Pharmaceutical Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRESSURIZED METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRESSURIZED METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRESSURIZED METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NON PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NON PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NON PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA PULMONARY DISEASE AEROSOL DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)